

Molnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region

Market Report | 2023-03-01 | 117 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

Global Molnupiravir market may register impressive growth in the forecast period, 2023-2027, due to rising demands for effective pharmaceuticals for the rising cases of COVID-19. The high prevalence of the disease coupled with the viral variant complicates the conditions of the patients and thus leading to severe conditions of the infection and causing death for the population, driving the growth of the global Molnupiravir market in the upcoming five years. Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster market growth.

Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus' RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.

Rising Instances of COVID-19 Drives Market Growth

Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.

As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong to

the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.

Investments & Advancement Wheel In Further Market Growth

Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.

In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.

Market Segmentation

The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The market analysis also studies the regional segmentation, divided among the Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.

Report Scope:

In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- -∏Molnupiravir Market, By Type:
- o[Influenza
- o∏Ebola
- o∏COVID-19
- o∏Others
- Molnupiravir Market, By Distribution Channel:
- o∏Hospital Pharmacies
- o

 Retail Pharmacies
- o
 ☐Online Pharmacies
- Molnupiravir Market, By Region:
- o∏North America
- -□United States
- -[Mexico
- -∏Canada
- o∏Asia-Pacific
- -□China
- -[]India
- -∐apan

Scotts International, EU Vat number: PL 6772247784

- -∏South Korea
- -□Australia
- -∏Vietnam
- Philippines
- -□Indonesia
- _ -∏Malaysia
- _____
- o∏Europe
- -[[France
- -□Germany
- -□United Kingdom
- -[Spain
- -[]Italy
- -□Denmark
- o∏South America
- -[Brazil
- -□Argentina
- -∏Colombia
- o∏Middle East & Africa
- -□South Africa
- -∏Saudi Arabia
- -□UAE
- -□Kenya

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Molnupiravir market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

-Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

- 1. □ Product Overview
- 2.

 ☐ Research Methodology
- 3. Impact of COVID-19 on Global Molnupiravir Market
- 4. Executive Summary
- 5. □Voice of Customer
- $5.1.\square$ Factors Contributing to Demand of Molnupiravir
- 5.2. Choice of Source for Procuring Molnupiravir
- 5.3. Source of Information
- 5.4. ☐ Barriers to Adoption of Molnupiravir
- 5.5. Brand Awareness
- 6. Pharmacodynamic Overview of Molnupiravir
- 6.1.

 Mechanism of Action
- 6.2. □ Absorption
- 6.3.

 ☐ Volume of Distribution
- 6.4. Protein Binding
- 6.5.

 Metabolism

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 6.6. Route of Elimination
- 6.7. ☐ Half Life
- 6.8. ☐ Clearance
- 7. Clinical Trials
- 7.1. □Ongoing Clinical Trials
- 7.2. Completed Clinical Trials
- 7.3. Terminated Clinical Trials
- 7.4. Clinical Trial Analysis
- 8. Patent Analysis
- 8.1. | Patent Granted (2017-2021)
- 8.2.

 □ Patent Applications Filed
- 9. □Global Molnupiravir Market Outlook
- 9.1.1. By Value & Volume
- 9.2. Market Share & Forecast
- 9.2.1. By Application (Influenza, Ebola, COVID-19, Others)
- 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 9.2.3. By Company (2021)
- 9.2.4. By Region
- 9.3. Pricing Analysis
- 9.4. ☐ Product Market Map
- 10. North America Molnupiravir Market Outlook
- 10.1. Market Size & Forecast □
- 10.1.1. By Value & Volume
- 10.2. Market Share & Forecast
- 10.2.1. By Application
- 10.2.2. By Distribution Channel
- 10.2.3. By Country
- 10.3. Pricing Analysis
- 10.4. North America: Country Analysis
- 10.4.1. United States Molnupiravir Market Outlook
- 10.4.1.1. ☐ Market Size & Forecast
- 10.4.1.1.1. □By Value & Volume
- 10.4.1.2. Market Share & Forecast
- 10.4.1.2.1. By Application
- 10.4.1.2.2. By Distribution Channel
- 10.4.2. ☐ Mexico Molnupiravir Market Outlook
- 10.4.2.1. Market Size & Forecast
- 10.4.2.1.1. By Value & Volume
- 10.4.2.2. Market Share & Forecast
- 10.4.2.2.1. By Application
- 10.4.2.2.. By Distribution Channel
- 10.4.3. ☐ Canada Molnupiravir Market Outlook
- 10.4.3.1. Market Size & Forecast
- 10.4.3.1.1. By Value & Volume
- $10.4.3.2. {\footnotesize | |} Market Share \& Forecast$
- 10.4.3.2.1. By Application

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 10.4.3.2.2. By Distribution Channel
- 11. Europe Molnupiravir Market Outlook
- 11.1. ☐ Market Size & Forecast ☐
- 11.1.1. By Value & Volume
- 11.2. Market Share & Forecast
- 11.2.1. By Application
- 11.2.2. ☐ By Distribution Channel
- 11.2.3. By Country
- 11.3. Pricing Analysis
- 11.4. Europe: Country Analysis
- 11.4.1. ☐ France Molnupiravir Market Outlook
- 11.4.1.1. ☐ Market Size & Forecast
- 11.4.1.1.1. ☐ By Value & Volume
- 11.4.1.2. Market Share & Forecast
- 11.4.1.2.1. By Application
- 11.4.1.2.2. ☐ By Distribution Channel
- 11.4.2. Germany Molnupiravir Market Outlook
- 11.4.2.1. Market Size & Forecast
- 11.4.2.1.1. By Value & Volume
- 11.4.2.2. Market Share & Forecast
- 11.4.2.2.1. By Application
- 11.4.2.2.2. By Distribution Channel
- 11.4.3. United Kingdom Molnupiravir Market Outlook
- 11.4.3.1. Market Size & Forecast
- 11.4.3.1.1. By Value & Volume
- 11.4.3.2. Market Share & Forecast
- 11.4.3.2.1. By Application
- 11.4.3.2.2. ☐ By Distribution Channel
- 11.4.4. Italy Molnupiravir Market Outlook
- 11.4.4.1. Market Size & Forecast
- 11.4.4.1.1. By Value & Volume
- 11.4.4.2. ☐ Market Share & Forecast
- 11.4.4.2.1. □By Application
- 11.4.4.2.2. By Distribution Channel
- 11.4.5. ☐ Spain Molnupiravir Market Outlook
- 11.4.5.1. Market Size & Forecast
- 11.4.5.1.1. By Value & Volume
- 11.4.5.2. Market Share & Forecast
- 11.4.5.2.1. By Application
- 11.4.5.2.2. ☐ By Distribution Channel
- 11.4.6. Denmark Molnupiravir Market Outlook
- 11.4.6.1. Market Size & Forecast
- 11.4.6.1.1. □By Value & Volume
- 11.4.6.2. Market Share & Forecast
- 11.4.6.2.1. By Application
- 11.4.6.2.2. ☐ By Distribution Channel
- 12. Asia-Pacific Molnupiravir Market Outlook

- 12.1. ☐ Market Size & Forecast ☐
- 12.1.1. By Value & Volume
- 12.2. Market Share & Forecast
- 12.2.1. By Application
- 12.2.2. ☐ By Distribution Channel
- 12.2.3. By Country
- 12.3. Pricing Analysis
- 12.4. Asia-Pacific: Country Analysis
- 12.4.1. ☐ China Molnupiravir Market Outlook
- 12.4.1.1. ☐ Market Size & Forecast
- 12.4.1.1.1. □By Value & Volume
- 12.4.1.2. ☐ Market Share & Forecast
- 12.4.1.2.1. By Application
- 12.4.1.2.2. ☐ By Distribution Channel
- 12.4.2. India Molnupiravir Market Outlook
- 12.4.2.1. Market Size & Forecast
- 12.4.2.1.1. By Value & Volume
- 12.4.2.2. Market Share & Forecast
- 12.4.2.2.1. By Application
- 12.4.2.2.. □By Distribution Channel
- 12.4.3. ☐ South Korea Molnupiravir Market Outlook
- 12.4.3.1. Market Size & Forecast
- 12.4.3.1.1. By Value & Volume
- 12.4.3.2. Market Share & Forecast
- 12.4.3.2.1. By Application
- 12.4.3.2.2. By Distribution Channel
- 12.4.4. Japan Molnupiravir Market Outlook
- 12.4.4.1. Market Size & Forecast
- 12.4.4.1.1. By Value & Volume
- 12.4.4.2. Market Share & Forecast
- 12.4.4.2.1. By Application
- 12.4.4.2.2. ☐ By Distribution Channel
- 12.4.5. □ Australia Molnupiravir Market Outlook
- 12.4.5.1. Market Size & Forecast
- 12.4.5.1.1. By Value & Volume
- 12.4.5.2. Market Share & Forecast
- 12.4.5.2.1. By Application
- 12.4.5.2.2. By Distribution Channel
- 12.4.6.

 ☐ Vietnam Molnupiravir Market Outlook
- 12.4.6.1. Market Size & Forecast
- 12.4.6.1.1. By Value & Volume
- 12.4.6.2. Market Share & Forecast
- 12.4.6.2.1. □By Application
- 12.4.6.2.2. ☐ By Distribution Channel
- 12.4.7. Philippines Molnupiravir Market Outlook
- 12.4.7.1. Market Size & Forecast
- 12.4.7.1.1. By Value & Volume

- 12.4.7.2. Market Share & Forecast
- 12.4.7.2.1. By Application
- 12.4.7.2.2. By Distribution Channel
- 12.4.8. Indonesia Molnupiravir Market Outlook
- 12.4.8.1. Market Size & Forecast
- 12.4.8.1.1. By Value & Volume
- 12.4.8.2. Market Share & Forecast
- 12.4.8.2.1. By Application
- 12.4.8.2.2. By Distribution Channel
- 12.4.9.1. Market Size & Forecast
- 12.4.9.1.1. □By Value & Volume
- 12.4.9.2. ☐ Market Share & Forecast
- 12.4.9.2.1. By Application
- 12.4.9.2.2. By Distribution Channel
- 13. South America Molnupiravir Market Outlook
- 13.1. Market Size & Forecast □
- 13.1.1. ☐ By Value & Volume
- 13.2. Market Share & Forecast
- 13.2.1. By Application
- 13.2.2. ☐ By Distribution Channel
- 13.2.3. By Country
- 13.3. □ Pricing Analysis
- 13.4. ☐ South America: Country Analysis
- 13.4.1. ☐ Brazil Molnupiravir Market Outlook
- 13.4.1.1. ☐ Market Size & Forecast
- 13.4.1.1.1. By Value & Volume
- 13.4.1.2. Market Share & Forecast
- 13.4.1.2.1. By Application
- 13.4.1.2.2. ☐ By Distribution Channel
- 13.4.2. Argentina Molnupiravir Market Outlook
- 13.4.2.1. Market Size & Forecast
- 13.4.2.1.1. ☐ By Value & Volume
- 13.4.2.2.

 ☐ Market Share & Forecast
- 13.4.2.2.1. By Application
- 13.4.2.2.. □By Distribution Channel
- 13.4.3. Colombia Molnupiravir Market Outlook
- 13.4.3.1. Market Size & Forecast
- 13.4.3.1.1. By Value & Volume
- 13.4.3.2. ☐ Market Share & Forecast
- 13.4.3.2.1. By Application
- 13.4.3.2.2. By Distribution Channel
- 14. ☐ Middle East and Africa Molnupiravir Market Outlook
- 14.1. Market Size & Forecast □
- 14.1.1. By Value & Volume
- 14.2. ☐ Market Share & Forecast
- 14.2.1. By Application

- 14.2.2. By Distribution Channel
- 14.2.3. By Country
- 14.3. Pricing Analysis
- 14.4. MEA: Country Analysis
- 14.4.1. South Africa Molnupiravir Market Outlook
- 14.4.1.1. ☐ Market Size & Forecast
- 14.4.1.1.1. By Value & Volume
- 14.4.1.2. Market Share & Forecast
- 14.4.1.2.1. By Application
- 14.4.1.2.2. □By Distribution Channel
- 14.4.2. ☐ Saudi Arabia Molnupiravir Market Outlook
- 14.4.2.1.1. By Value & Volume
- 14.4.2.2. Market Share & Forecast
- 14.4.2.2.1. By Application
- 14.4.2.2.2. ☐ By Distribution Channel
- 14.4.3. ☐ UAE Molnupiravir Market Outlook
- 14.4.3.1. Market Size & Forecast
- 14.4.3.1.1. By Value & Volume
- 14.4.3.2. Market Share & Forecast
- 14.4.3.2.1. By Application
- 14.4.3.2.2. By Distribution Channel
- 14.4.4. ☐ Kenya Molnupiravir Market Outlook
- 14.4.4.1. Market Size & Forecast
- 14.4.4.1.1. ☐ By Value & Volume
- 14.4.4.2. Market Share & Forecast
- 14.4.4.2.1. By Application
- 14.4.4.2.2. ☐ By Distribution Channel
- 15. Market Dynamics
- $15.1. \square Drivers$
- 15.2. ☐ Challenges
- 17. □Competitive Landscape
- 17.1. □Company Profiles
- 17.1.1. Company Details
- 17.1.2. ☐ Financials (As reported)
- 17.1.3. Key Market Focus and Geographical Presence
- 17.1.4. Pricing of Target Products
- 17.1.5. Market positioning
- 17.2. Merck Sharp & Dohme Corp.
- 17.3. Everest Organics Limited
- 17.4. ☐ Optimus Drugs Pvt Ltd.
- 17.5. Dr. Reddy's Laboratories Ltd
- 17.6. Cipla Limited
- 17.7. Mylan N.V.
- $17.8. \\ \square Emcure\ Pharmaceuticals\ Ltd.$
- 17.9. Sun Pharmaceutical Industries Limited

 $17.10. \\ \square Hetero \ Drugs \ Ltd.$

17.11. Torrent Pharmaceuticals Ltd.

 $18. \\ \square Strategic \ Recommendations$



To place an Order with Scotts International:

☐ - Print this form

Molnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region

Market Report | 2023-03-01 | 117 pages | TechSci Research

☐ - Complete the r	elevant blank fields and sign			
Send as a scan	ned email to support@scotts-interr	national.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$4900.00
	Multi-User License			\$5900.00
	Custom Research License			\$8900.00
			VA	Т
			Tota	al
	rant license option. For any questions p			
∐** VAT will be added a	at 23% for Polish based companies, indi	ividuals and EU based cor	mpanies who are unable to provide	a valid EU Vat Numbe
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / N	IIP number*	
Address*		City*		
Zip Code*		Country*		

Scotts International. EU Vat number: PL 6772247784

Date	2025-06-25
Signature	